It’s time to start thinking about seasonal vaccinations. Getting those annual jabs isn’t quite as simple as it was before the ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

Respiratory syncytial virus, or RSV, typically presents as mild, with symptoms similar to the common cold for adults and ...

Anyone who got sick with COVID-19 during the summer wave in South Florida has some protection against a future infection, but ...

Anyone who got sick with COVID-19 during the summer wave in South Florida has some protection against a future infection, but ...

The CDC’s vaccine advisors on Thursday maintained that respiratory syncytial virus immunization is only recommended for ...

Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.

Last week, GlaxoSmithKline and Northwestern University filed separate lawsuits against Moderna, accusing its mRNA-based vaccines of ...

On Thursday, GSK plc (NYSE:GSK) revealed new preliminary data for Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) in ...

The company will use the funds to advance its pipeline of cancer-targeting preclinical candidates to the “clinic-ready” stage ...

“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...